C20orf173: A Key Regulator of HSP70s and Potential Drug Targets

Target Name: C20orf173

NCBI ID: G140873

C20orf173

Other Name(s): CT173_HUMAN | chromosome 20 open reading frame 173 | dJ477O4.4 | Chromosome 20 open reading frame 173, transcript variant 1 | Uncharacterized protein C20orf173

C20orf173: A Key Regulator of HSP70s and Potential Drug Targets

C20orf173 (CT173_HUMAN), a protein located in the human proteasome, is a key regulator of the chaperone HSP70 family. HSP70s are a family of proteins that play a crucial role in protein folding and localization, and their dysfunction has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The C20orf173 protein is a 20-kDa protein that is expressed in various tissues and cells of the human body. It is a member of the HSP70 family and is characterized by a N-terminal alpha-helix, a central beta-sheet, and a C-terminal hypervariable region (HVR). The HVR is responsible for the protein's unique structure and function and is involved in its stability, localization, and interactions with other proteins.

The C20orf173 protein has been extensively studied for its role in the regulation of protein function and its potential as a drug target. One of the most significant findings of these studies is that the C20orf173 protein can interact with a variety of protein substrates, including casein, alpha-heparin, and drug molecules. This interaction between the protein and its substrates suggests that the C20orf173 protein could be a useful biomarker or drug target in diseases where protein misfolding is a known risk factor or where targeting the regulation of protein function could be beneficial.

In addition to its potential as a drug target, the C20orf173 protein has also been shown to be a promising biomarker for a number of diseases. For example, studies have shown that the levels of the C20orf173 protein are elevated in the brains of individuals with Alzheimer's disease, and that it is involved in the regulation of the aggregation of beta-amyloid peptides. Similarly, the protein has been shown to be involved in the regulation of protein function in a variety of neurodegenerative diseases, including Parkinson's disease and Huntington's disease.

The C20orf173 protein is also of interest as a potential therapeutic target for cancer. Many studies have shown that the regulation of protein function is closely correlated with the regulation of cancer cell growth and survival. The C20orf173 protein has been shown to be involved in the regulation of protein function in a variety of cancer types, including breast, lung, and ovarian cancers. Therefore, targeting the C20orf173 protein with small molecules or other therapeutic agents may be a promising strategy for the treatment of cancer.

In conclusion, the C20orf173 protein is a key regulator of the chaperone HSP70 family and has a wide range of potential as a drug target or biomarker. Its interaction with protein substrates and its regulation of protein function make it an attractive target for small molecules and other therapeutic agents. Further research is needed to fully understand the role of the C20orf173 protein in disease and to develop effective therapies based on its targeting.

Protein Name: Chromosome 20 Open Reading Frame 173

The "C20orf173 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C20orf173 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets